Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Celgene Corporation (CELG)’s Fastest-Growing Drug

Page 1 of 2

What’s the fastest growing drug in Celgene Corporation (NASDAQ:CELG)‘s portfolio? It isn’t Revlimid, Vidaza, or Abraxane. All three of those drugs are experiencing strong sales, but none can match the growth rate of Istodax. In this round of our continuing series on Celgene’s products and pipeline, we’ll take a look at this fast-growing but still-lagging drug.

Celgene Corporation (NASDAQ:CELG)From dirt to dollars
First came dirt. In 1994, Japanese researchers with Fujisawa Pharmaceutical first announced discovery of a molecule that they called romidepsin. The molecule was isolated from bacteria found in a soil sample from Yamagata Prefecture in Japan. As the researchers experimented with romidepsin, they discovered that it possessed the ability to kill cancer cells.

Privately held Gloucester Pharmaceuticals licensed romidepsin, also known as FK228 and depsipeptide, from Fujisawa in 2004. Gloucester advanced the drug into late-stage studies, renaming it as Istodax. The U.S. Food and Drug Administration approved Isotdax in November 2009 as a second-line treatment for cutaneous T-cell lymphoma, or CTCL.

Celgene didn’t wait long to enter the picture. One month after the FDA approval, the company announced plans to buy Gloucester. The deal closed in January 2010 for $340 million, plus up to $300 million more if Istodax met certain milestones. Celgene soon began selling the drug and pursued FDA approval for its use in treating peripheral T-cell lymphoma, or PTCL. The company also filed for European regulatory approval for PTCL.

Istodax sales started off slowly. However, things began to pick up somewhat after the FDA granted accelerated approval for Istodax as a second-line treatment for PTCL in mid-2011.

Source: Company 10K.

The growth rates over the past three years were nice and made Istodax the company’s fastest-growing product. Celgene has begun to see a return on its investment in Gloucester, but the crown jewel that it acquired from the smaller company still isn’t making much of a dent on total revenue.

Source: Company 10K.

Euro no good — and other challenges
One reason why Istodax sales haven’t taken off even more quickly is Europe. The European Committee for Medicinal Products for Human Use, or CHMP, announced a negative recommendation for the drug in July 2012 for treating PTCL. Celgene requested a re-examination of this opinion, but CHMP confirmed the negative recommendation in November.

The problem relates to proving the clinical benefit of Istodax. The FDA’s accelerated approval for the drug in treating PTCL was based on response rate rather than improved survival rates or other clinical benefits. Without additional studies to convince CHMP, Istodax’s European future doesn’t look good.

Celgene’s management didn’t even mention Istodax in the company’s fourth-quarter earnings call and doesn’t show any other studies for the drug on its pipeline. However, the U.S. National Institutes for Health lists one phase 1/2 study for the drug sponsored by Celgene.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!